IP Library Granted Patent US 9,308,254
Granted Patent B2
US 9,308,254 · App. 13/579,555 · Granted Apr 12, 2016

Method for treatment of post operative cognitive dysfunction

Inventors: Mervyn Maze (San Francisco, CA); Marc Feldman (London, GB); Niccolo Terrando (San Francisco, CA); Mario Cibelli (London, GB); Daqing Ma (London, GB); Michael Fertleman (London, GB)
Assignee: IMPERIAL INNOVATIONS LIMITED
A61K39/3955C07K14/525C07K16/241A61K2039/505C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,308,254
App. No.
13/579,555
Granted
Apr 12, 2016
Kind
B2
Abstract

The present invention provides method, uses and agents for preventing or reducing cognitive decline in a patient following a planned inflammatory trigger. Such planned inflammatory trigger can be a surgical procedure or chemotherapy. The invention further provides methods, uses and agents for reducing cognitive decline in a patient with a cognitive disorder, wherein said patient has been exposed to an inflammatory trigger. Pharmaceutical compositions and kits are also provided.

Claims (5)

1. A method for the treatment or prophylaxis of post operative cognitive dysfunction (POCD) in a patient following surgery in said patient, the method comprising administering a therapeutically effective amount of an anti-Tumour Necrosis Factor alpha (anti-TNFα) antibody and a therapeutically effective amount of an Interleukin 1 (IL-1) receptor antagonist to said patient.

2. The method according to claim 1 , wherein the anti-TNFα antibody and the IL-1 receptor antagonist are administered to the patient, before commencement of a surgical procedure; during a surgical procedure; and/or after completion of a surgical procedure, on said patient.

3. The method according to claim 2 , wherein the anti-TNFα antibody and the IL-1 receptor antagonist are administered immediately before and/or up to 1 hour after completion of said surgical procedure.

4. The method according to claim 1 , which is for preventing or reducing post operative cognitive dysfunction (POCD) when the patient is at risk of developing at least one of delirium, Alzheimer's Disease, multiple sclerosis, stroke, Parkinson's Disease, Huntington's Disease, dementia, frontotemporal dementia, vascular dementia, HIV dementia, Post-Traumatic Stress Disorder and/or Rheumatoid Arthritis.

5. The method according to claim 1 , wherein the patient is a human.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2013
From: IMPERIAL INNOVATIONS LIMITED
To: THE KENNEDY TRUST FOR RHEUMATOLOGY RESEARCH
Reel/Frame 030176/0799 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2012
From: MAZE, MERVYN; FELDMAN, MARC; TERRANDO, NICCOLO; CIBELLI, MARIO; MA, DAQING; FERTLEMAN, MICHAEL
To: IMPERIAL INNOVATIONS LIMITED
Reel/Frame 029327/0043 →
Continuity (2)
Provisional Application 61305500 · Feb 17, 2010
Related Publication 20130084299A1 · Apr 4, 2013